drugset / Trial / NCT04725110
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation.
Timeline
- Start
- 2026-01-15
- Primary completion
- 2030-10-15
- Completion
- 2031-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liothyronine | Small molecule | 50 ug | Other |